AHR and serum lipopolysaccharide activity: Persistent, high-affinity AhR agonists such as TCDD represent a clear risk for epithelial barrier dysfunction and systemic endotoxemia, whereas controlled activation by dietary or pharmacological ligands may enhance barrier resilience and mucosal immunity [21].